CalciMedica Inc

CALC

Company Profile

  • Business description

    CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

  • Contact

    505 Coast Boulevard South
    Suite 307
    La JollaCA92037
    USA

    T: +1 858 952-5500

    E: [email protected]

    https://www.calcimedica.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    15

Stocks News & Analysis

stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.
stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5015.300.17%
CAC 407,744.4153.81-0.69%
DAX 4024,041.90265.90-1.09%
Dow JONES (US)44,502.44179.370.40%
FTSE 1009,023.8110.820.12%
HKSE25,130.03135.890.54%
NASDAQ20,892.6981.49-0.39%
Nikkei 22539,774.9244.19-0.11%
NZX 50 Index12,830.133.61-0.03%
S&P 5006,309.624.020.06%
S&P/ASX 2008,677.209.000.10%
SSE Composite Index3,581.8622.070.62%

Market Movers